Carcinoid syndrome

Cabozantinib

Cabozantinib, a multiple receptor tyrosine-kinase inhibitor, inhibits tumour growth and angiogenesis. Cabozantinib has been found to significantly improve progression-free survival compared to placebo in patients with previously treated, progressive advanced extrapancreatic or pancreatic neuroendocrine tumors.[62]Chan JA, Geyer S, Zemla T, et al. Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors. N Engl J Med. 2025 Feb 13;392(7):653-65. https://pmc.ncbi.nlm.nih.gov/articles/PMC11821447 http://www.ncbi.nlm.nih.gov/pubmed/39282913?tool=bestpractice.com ​